Cytomegalovirus Infection Is Associated With Cardiac Allograft Rejection and Atherosclerosis

JAMA: The Journal of the American Medical Association

Volumn 261, Issue 24, 1989, Pages 3561-3566

  Grattan, Mark T ^a   Moreno Cabral, Carlos E ^a   Starnes, Vaughn A ^a   Oyer, Phillip E ^a   Stinson, Edward B ^a   Shumway, Norman E ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; GANCICLOVIR; OKT 3; PREDNISONE; THYMOCYTE ANTIBODY;

ATHEROSCLEROSIS; CYTOMEGALOVIRUS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL;

ADULT; CORONARY ARTERIOSCLEROSIS; CYCLOSPORINS; CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; MIDDLE AGE; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0024320881     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1989.03420240075030     Document Type: Article

References (33)

1. Dummer JS, White LT, Ho M, Griffith BP, Hardesty RL, Bahnson HT. Morbidity of cytomegalovirus infection in recipients of heart or heart-lung transplants who received cyclosporine. J Infect Dis. 1985;152:1182-1191.
2. Brooks RG, Hofflin JM, Jamieson SW, Stinson EB, Remington JS. Infectious complications in heart-lung transplant patients. Am J Med. 1985;79:412-422.
3. Meiselman MS, Cello JP, Margaretten W. Cytomegalovirus colitis: report of the clinical, endoscopic, and pathologic findings in two patients with the acquired immune deficiency syndrome. Gastroenterology. 1985;88:171-175.
4. Rand KH, Pollard RB, Merigan TC. Increased pulmonary superinfections in cardiac transplant patients undergoing primary cytomegalovirus infection. N Engl J Med. 1978;298:951-953.
5. Burke CM, Glanville AR, Macoviak JA, et al. The spectrum of cytomegalovirus infection following human heart-lung transplantation. J Heart Transplant. 1986;5:267-272.
6. Lopez C, Simmons RL, Mauer SM, Park B, Najarian JS, Good RA. Virus infections may trigger rejection in immunosuppressed renal transplant recipients. Proc Clin Dial Transplant Forum. 1972;2:107-111.
7. Light JA, Burke DS. Association of cytomegalovirus (CMV) infections with increased recipient mortality following transplantation. Transplant Proc. 1979;11:79-82.
8. Wreghitt TG, Hakin M, Gray JJ, et al. A detailed study of cytomegalovirus infections in the first 160 heart and heart/lung transplant recipients at Papworth Hospital, Cambridge, England. Transplant Proc. 1987;19:2495-2496.
9. Preiksaitis JK, Rosno S, Grumet C, Merigan TC. Infections due to herpesviruses in cardiac transplant recipients: role of the donor heart and immunosuppressive therapy. J Infect Dis. 1983; 147:974-981.
10. Billingham ME. The postsurgical heart: the pathology of cardiac transplantation. Am J Cardio-vasc Pathol. 1988;1:319-334.
11. Cutler SJ, Ederer F. Maximum utilization of the life table in analyzing survival. J Chronic Dis. 1958;8:699-712.
12. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons Inc; 1980.
13. Glantz SA. Primer of Biostatistics. 2nd ed. New York, NY: McGraw-Hill International Book Co; 1987.
14. Fryd DS, Peterson PK, Ferguson RM, Simmons RL, Balfour HH, Najarian JS. Cytomegalovirus as a risk factor in renal transplantation. Transplantation. 1980;36:436-439.
15. Richardson WP, Colvin RB, Cheeseman SH, et al. Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med. 1981;305:57-63.
16. Rubin RH, Tolkoff-Rubin NE, Oliver D, et al. Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation. 1985;40:243-249.
17. Smiley ML, Wlodaver CG, Grossman RA, et al. The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation. Transplantation. 1985;40:157-161.
18. Gao ZS, Schroeder JS, Alderman EL, et al. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation. 1987;76:V56-V61.
19. Groenewegen G, Buurman WA, van der Linden CJ. Lymphokine dependence of in vivo expression of MHC class II antigens by endothelium. Nature. 1985;316:361-363.
20. Skoskiewicz MJ, Colvin RB, Schneeberger EE, Russell PS. Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by gamma-interferon. J Exp Med. 1985;162:1645-1664.
21. Pober JS, Gimbrone MA, Cotran RS, et al. Ia expression by vascular endothelium is inducible by activated T cells and by human gamma-interferon. J Exp Med. 1983;157:1339-1353.
22. Pober JS, Collins T, Gimbrone MA, et al. Lymphocytes recognize human vascular endothelial and dermal fibroblast Ia antigens induced by recombinant immune interferon. Nature. 1983;305:726-729.
23. Payne JE, Fiala M, Spencer M, Chatterjee SN, Berne TV. Cytomegalovirus antigen-antibody complexes in biopsy specimens in renal allograft rejection. Surg Forum. 1974;25:273-275.
24. Baldwin WM, van Es A, Valentijn RM, van Gemert GW, Daha MR, Vanes LA. Increased IgM and IgM immune complex-like material in the circulation of renal transplant recipients with primary cytomegalovirus infections. Clin Exp Immunol. 1982;50:515-524.
25. Von Willebrand E, Pettersson E, Ahonen J, Hayry P. CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation. 1986;45:394-401.
26. Van Es A, Valdwin WM, Oljans PJ, Tanke HJ, Ploem JS, van Es LA. Expression of HLA-DR on T lymphocytes following renal transplantation, and association with graft-rejection episodes and cytomegalovirus infection. Transplantation. 1984;37: 65-69.
27. Fujinami RS, Nelson JA, Walker L, Oldstone MB. Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR beta chain: a means for graft rejection and immunosuppression. J Virol. 1988;62:100-105.
28. Beck S, Barrell BG. Human cytomegalovirus encodes a glycoprotein homologous to MHC class I antigens. Nature. 1988;331:269-272.
29. Wiley D. Molecular immunology: MHC gene in cytomegalovirus. Nature. 1988;331:209-210.
30. Fabricant CG, Hajjar DP, Minich CR, Fabricant J. Herpesvirus infection enhances cholesterol and cholestryl ester accumulation in cultured arterial smooth muscle cells. Am J Pathol. 1981;105: 176-184.
31. Adam E, Probtsfield JL, Burek J, et al. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet. 1987;8554:291-293.
32. Brayman KL, Dafoe DC, Smythe WR, et al. Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine: interim results of a randomized clinical trial. Arch Surg. 1988;123:1502-1508.
33. Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med. 1986;314:801-805.